China Meheco Group's Subsidiary Receives Approval for Lincomycin Hydrochloride Injection Generic Drug Consistency Evaluation

Stock News09-23

China Meheco Group Co.,Ltd. (600056.SH) announced that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd., has recently received the "Drug Supplementary Application Approval Notice" for Lincomycin Hydrochloride Injection issued by the National Medical Products Administration. The drug has successfully passed the generic drug quality and efficacy consistency evaluation.

Lincomycin Hydrochloride Injection is primarily used for treating serious infections caused by sensitive bacterial strains including Streptococcus, Pneumococcus, and Staphylococcus. According to relevant national policies, drug varieties that pass consistency evaluation will receive greater support in areas such as medical insurance payments and medical institution procurement.

The successful completion of the generic drug quality and efficacy consistency evaluation for Tianfang Pharmaceutical's Lincomycin Hydrochloride Injection is expected to enhance the product's market competitiveness and further expand its market share.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1154383120?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-23 16:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154383120","market":"fut","top_or_hot":-1,"title":"China Meheco Group's Subsidiary Receives Approval for Lincomycin Hydrochloride Injection Generic Drug Consistency Evaluation","media":"Stock News","content":"<p>China Meheco Group Co.,Ltd. (600056.SH) announced that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd., has recently received the \"Drug Supplementary Application Approval Notice\" for Lincomycin Hydrochloride Injection issued by the National Medical Products Administration. The drug has successfully passed the generic drug quality and efficacy consistency evaluation.</p>\n<p>Lincomycin Hydrochloride Injection is primarily used for treating serious infections caused by sensitive bacterial strains including Streptococcus, Pneumococcus, and Staphylococcus. According to relevant national policies, drug varieties that pass consistency evaluation will receive greater support in areas such as medical insurance payments and medical institution procurement.</p>\n<p>The successful completion of the generic drug quality and efficacy consistency evaluation for Tianfang Pharmaceutical's Lincomycin Hydrochloride Injection is expected to enhance the product's market competitiveness and further expand its market share.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Meheco Group's Subsidiary Receives Approval for Lincomycin Hydrochloride Injection Generic Drug Consistency Evaluation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Meheco Group's Subsidiary Receives Approval for Lincomycin Hydrochloride Injection Generic Drug Consistency Evaluation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-23 16:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Meheco Group Co.,Ltd. (600056.SH) announced that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd., has recently received the \"Drug Supplementary Application Approval Notice\" for Lincomycin Hydrochloride Injection issued by the National Medical Products Administration. The drug has successfully passed the generic drug quality and efficacy consistency evaluation.</p>\n<p>Lincomycin Hydrochloride Injection is primarily used for treating serious infections caused by sensitive bacterial strains including Streptococcus, Pneumococcus, and Staphylococcus. According to relevant national policies, drug varieties that pass consistency evaluation will receive greater support in areas such as medical insurance payments and medical institution procurement.</p>\n<p>The successful completion of the generic drug quality and efficacy consistency evaluation for Tianfang Pharmaceutical's Lincomycin Hydrochloride Injection is expected to enhance the product's market competitiveness and further expand its market share.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600056","symbol_name":"中国医药","start_time":0,"source_url":"","article_id":"1154383120","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154383120","pubTimestamp":1758615264,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"China Meheco Group Co.,Ltd. (600056.SH) announced that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd., has recently received the \"Drug Supplementary Application Approval Notice\" for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600056":"中国医药","BK0175":"白马股","BK0010":"央企","BK0082":"国资改革","BK0250":"批发","BK0028":"国家队","BK0185":"二线龙头","BK0188":"融资融券"},"translate_title":"中国迈赫科集团子公司获得盐酸林可霉素注射液仿制药一致性评价批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600056":1},"content_text":"China Meheco Group Co.,Ltd. (600056.SH) announced that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd., has recently received the \"Drug Supplementary Application Approval Notice\" for Lincomycin Hydrochloride Injection issued by the National Medical Products Administration. The drug has successfully passed the generic drug quality and efficacy consistency evaluation.\nLincomycin Hydrochloride Injection is primarily used for treating serious infections caused by sensitive bacterial strains including Streptococcus, Pneumococcus, and Staphylococcus. According to relevant national policies, drug varieties that pass consistency evaluation will receive greater support in areas such as medical insurance payments and medical institution procurement.\nThe successful completion of the generic drug quality and efficacy consistency evaluation for Tianfang Pharmaceutical's Lincomycin Hydrochloride Injection is expected to enhance the product's market competitiveness and further expand its market share.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1154383120","isCrawlerRequest":true}